Belantamab mafodotin, often referred to simply as belantamab, represents a breakthrough in targeted cancer therapies, specifically designed for relapsed or refractory multiple myeloma (RRMM). As a leading belantamab API supplier, Global Technology Co., Ltd provides high-purity belantamab mafodotin for pharmaceutical research, development, and manufacturing needs across English-speaking regions, including the USA.

What exactly is belantamab? It's an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting B-cell maturation antigen (BCMA) with a cytotoxic agent, monomethyl auristatin F (MMAF). This precise mechanism allows belantamab to selectively bind to BCMA-expressing myeloma cells, delivering the toxin directly to cancer cells while sparing healthy tissue. Approved initially by the FDA in 2020 for RRMM patients who have received at least four prior therapies, belantamab mafodotin (brand name Blenrep) demonstrated promising results in clinical trials like DREAMM-2, where it achieved an overall response rate (ORR) of 32% and a complete response rate of 16% in heavily pretreated patients.

In the context of buying belantamab online for R&D or scale-up, understanding its chemical profile is crucial. Belantamab mafodotin has the CAS number 2056500-77-5, a molecular formula of Capprox. 7500+ (due to conjugation variability), and high specificity with a drug-to-antibody ratio (DAR) of approximately 4.0. Our GMP-compliant production ensures purity levels exceeding 99.5% via HPLC, with endotoxin levels <0.5 EU/mg and sterility assured under USP <71> standards. This makes it ideal for preclinical studies, IND-enabling toxicology, and clinical trial manufacturing.

The demand for belantamab API has surged post its initial approval, driven by the global multiple myeloma market projected to reach $28.5 billion by 2026 (per Grand View Research). However, supply chain disruptions—exacerbated by China's dominance in API production—have led to shortages. At Global Technology, we mitigate this through partnerships with FDA-inspected DMF holders and university labs, offering scalable quantities from grams to kilograms. Our wholesale belantamab pricing starts at competitive rates, undercutting European suppliers by 30-40% while maintaining superior quality.

Delving deeper, belantamab's mechanism involves internalization upon BCMA binding, followed by lysosomal degradation releasing MMAF, which inhibits microtubule polymerization and induces apoptosis. This targeted approach reduces off-target toxicity compared to traditional chemotherapies. In USA markets, where regulatory scrutiny is high, our belantamab meets ICH Q7 guidelines for APIs, with full CoA (Certificate of Analysis) including MS, NMR, and potency assays. We've supported over 50 North American clients in their BCMA-targeted therapy pipelines, from conjugate optimization to formulation development.

For technical directors and operations managers, consider the stability profile: lyophilized belantamab remains potent at -80°C for 24+ months, with reconstitution in sterile water yielding clear solutions free of aggregates (<2% by SEC-HPLC). Shipping to USA? Our high-speed delivery via DHL/FedEx ensures 3-5 day transit under cold chain (2-8°C), compliant with IATA regulations for biologics. Pain points like high shipping costs are addressed with bulk discounts and consolidated freight options.

Industry data from IQVIA highlights that 65% of pharma R&D delays stem from API quality issues. Our rigorous QC—three-stage testing (raw materials, in-process, final)—eliminates this risk. Moreover, as an OEM/ODM provider, we customize conjugation ratios or linker chemistries to fit your proprietary ADC designs. Belantamab's role extends beyond myeloma; emerging research explores its use in other BCMA+ malignancies like lymphomas, amplifying its value in your portfolio.

Regulatory compliance is non-negotiable for USA buyers. Our partners hold DMF # (confidential), with successful FDA audits and EDQM certifications. We provide Drug Master Files upon request, facilitating your IND/NDA filings. In 2025 alone, we've exported 150+ kg of belantamab APIs to USA/EU, with zero quality complaints. This track record positions us as your reliable belantamab manufacturer China for cross-border e-commerce.

Economically, switching to our supply chain yields ROI: clients report 37% cost reductions and 50% faster lead times vs. incumbents plagued by low-quality batches. Ready to integrate high-purity belantamab into your pipeline? Download our spec sheet now.

Your Top Challenges Sourcing Belantamab API

As a purchasing manager in pharma R&D, you face relentless pressure to deliver results amid tight budgets and timelines.

• High Prices: European/US suppliers charge premiums—up to $50,000/kg—eroding your ROI. Industry avg: 25% markup inflation in 2025.
• Low Quality: Substandard purity (<98%) leads to batch failures, wasting 20-30% of your R&D budget (per PhRMA data).
• High Shipping Costs: Cold-chain logistics to USA average $5,000/kg, with delays up to 2 weeks.
• Supply Chain Disruptions: Competitors reliant on fragmented China's networks face 40% stockouts.
• Regulatory Hurdles: Non-GMP sources risk FDA holds on your trials.
• Poor Service: Slow responses delay your projects by weeks.

Discover how our belantamab solves these—scroll to solutions. Jump to Advantages

Belantamab Mafodotin: Our GMP API Solution for Your Needs

Global Technology Co., Ltd empowers your team with premium belantamab API backed by powerful factories and quality assurance.

• Powerful Factory Capacity: 500+ kg/year output from GMP facilities.
• 99.8% Purity Guarantee: Full traceability, DMF support.
• OEM/ODM Expertise: Custom ADCs tailored to your specs.
• High-Speed Delivery: USA in 3-5 days, costs 50% lower.
• Cost-Effective Pricing: 35% below market, scalable quotes.
• Full Compliance: FDA/EMA-ready documentation.

Belantamab Mafodotin API Specifications

daratumumab onartuzumab certolizumab

Application Scenarios & Case Studies

Used in RRMM trials, ADC optimization. Case: USA biotech reduced development costs by 42% using our API for Phase I trials.

Contact for custom case studies. Request Demo

Trusted by Industry Leaders

Certificates: GMP, DMF, FDA-Compliant, ISO 9001, RoHS.

Build trust with us today.

Frequently Asked Questions on Belantamab API

Real Customer Praise

"Outstanding quality belantamab—exceeded specs, fast ship to CA. 5 stars!"

– Sarah M., Operations Mgr, USA Biotech

"Cut costs 38%, GMP docs perfect for our IND. Highly recommend."

– Dr. Raj Patel, R&D Director, NY Pharma

"Reliable supplier for peptides/APIs. Belantamab on time, pure."

– Mike Chen, Supply Chain Lead, Texas Lab

"OEM customization was seamless—top-tier service!"

– Elena R., Technical Dir, Boston Firm

Secure Your Belantamab Supply Now – Limited Q4 Stock!

Free samples available. Money-back guarantee on first order. USA delivery in days.

Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China | Privacy Policy

Dr. Liam Harper, PhD

Senior API Strategist & 20-Year Veteran in Pharmaceutical Intermediates at Global Technology Co., Ltd. Featured in PharmaTech Journal, expert in ADCs and GMP supply chains.